anx_II__cpt_1__cpt_1__cpt_1__table_1__row_119

Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products Text with EEA relevance · European Union

8.13.3. Endocrine disruption If there is any evidence from in vitro, repeat dose or reproduction toxicity studies, that the active substance may have endocrine disrupting properties then additional information or specific studies shall be required to: elucidate the mode/mechanism of action provide sufficient evidence for relevant adverse effects For evaluation of consumer safety of active substances that may end up in food or feed, it is necessary to conduct toxicity studies by the oral route ADS

← anx_II__cpt_1__cpt_1__cpt_1__table_1__row_118__cell_3 · All articles · anx_II__cpt_1__cpt_1__cpt_1__table_1__row_119__cell_1 →

Source: EUR-Lex (Cellar) · retrieved 2026-10-29 · Text as adopted (Official Journal); later amendments are not incorporated in this text.